AICAR

AICAR is a small molecule sold online as an “exercise in a pill.” It is not a peptide, not a hormone, and not a SARM (selective androgen receptor modulator — a class of muscle-building drugs). It is an AICA-riboside that switches on a metabolic enzyme called AMPK. Its whole reputation comes from one 2008 mouse study where couch-potato mice given AICAR ran much farther. In people, the real medical track record is for two completely different uses — protecting the heart during surgery and treating a blood cancer — and both of those stalled. There is no credible human evidence that it improves endurance, body composition, lifespan, recovery, or how you look.

What it is

AICAR’s full chemical name is 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside. The version that drug companies developed is called acadesine (CAS 2627-69-2). It is a small-molecule purine nucleoside analog (an AICA-riboside) — not a peptide. Once it gets inside your cells, they convert it into a molecule called ZMP, which looks a lot like AMP (a signal cells use to track their energy levels). ZMP fakes a “low fuel” signal and so switches on AMP-activated protein kinase (AMPK) — the cell’s main energy-management switch, which controls how cells take in glucose (blood sugar), burn fat, and build new mitochondria (the tiny power plants inside cells). That switch is the reason people call it an “exercise mimetic” (a drug meant to copy the effects of working out).

One honest catch: a lot of what AICAR does has nothing to do with AMPK at all. A 2021 review that pooled the research (Višnjić et al., Cells) says plainly that “numerous AICAr effects, previously attributed to AMPK activation, are in fact AMPK-independent.” And, surprisingly, a 2007 human muscle study (described below) found that glucose uptake went up without any measurable jump in muscle AMPK activity. So even the one short-term human effect we can actually measure does not fit the tidy “AMPK activator” story.

The claims

In the biohacking and fitness world, AICAR is pitched as “exercise in a pill”: more endurance and aerobic capacity, fat loss, a faster metabolism and better blood-sugar handling, quicker recovery, and anti-aging or “longevity” perks — usually with a “non-hormonal, train less / gain more” angle. Almost all of this is borrowed from mouse data. None of it holds up in humans.

What the evidence actually shows

Animal / preclinical (the strongest “exercise mimetic” data):

• The study that started it all is Narkar, Evans et al., “AMPK and PPARδ agonists are exercise mimetics,” Cell 2008 (134(3):405–415). In sedentary mice, four weeks of AICAR boosted running endurance by ~44% and turned on genes tied to fat-burning metabolism. This is where the hype began — but remember, it is a mouse result, not proof in people.
• There is a lot more rodent and lab-dish research on diabetes, fat-burning, and other effects, but all of it is still preclinical (done in animals or cells, not humans).

Human evidence (much thinner — and not for endurance or longevity):

• Short-term muscle glucose uptake — Cuthbertson et al., Diabetes 2007 (56(8):2078–2084). In healthy men, a single dose of AICAR briefly raised how much glucose muscle took in by ~2.1-fold (for comparison, exercise raised it ~4.7-fold) and bumped up whole-body glucose disposal by ~7% — but with no measurable rise in muscle AMPK activity (the AMPK α1/α2 activity and phosphorylation, two markers of the enzyme switching on, didn’t change). That undercuts the simple mechanism. And this was a quick one-off physiology test, not evidence that training results improve.
• Protecting the heart during bypass surgery — RED-CABG trial, JAMA 2012 (Newman et al.) (308(2):157–164). This was a big randomized trial of 3,080 patients (out of 7,500 originally planned), and it was stopped early because it wasn’t working. The main combined outcome was 5.0% with placebo versus 5.1% with acadesine (OR 1.01, 95% CI 0.73–1.41) — essentially no difference. An earlier analysis pooling 5 trials and 4,043 patients (Mangano, JAMA 1997) had hinted at a benefit, but this larger, more definitive trial came back negative.
• Relapsed/refractory CLL (a blood cancer) — Van Den Neste et al., Cancer Chemother Pharmacol 2013 (71(3):581–591). A small study of 24 patients given acadesine by IV figured out the highest dose people could tolerate (210 mg/kg) but did not move forward toward approval. The lab reasoning behind it (Campàs et al., Blood 2003) was that acadesine pushes B-CLL cancer cells to self-destruct (a process called apoptosis — it happened in all 70 samples tested) while barely touching healthy T lymphocytes (a type of immune cell).

Bottom line on evidence: the only human data come from two medical uses that both stalled, plus one short-term glucose-uptake study. There is no credible human evidence that AICAR improves endurance, body composition, lifespan, recovery, or appearance. Using it for those goals is just guessing based on mouse results.

Legal and regulatory status

• AICAR is not an approved drug anywhere — not for performance, longevity, metabolism, or looks. It never earned marketing approval, and both of its clinical programs (heart protection and the blood cancer) failed or stalled.
• On the consumer market it is sold only as a research chemical labeled “not for human consumption.” It is not a dietary supplement and not a cosmetic ingredient with any real approval. Products like this aren’t checked for purity or even whether they contain what the label says.
• Anti-doping (WADA): AICAR is banned at all times (both in and out of competition) on the WADA Prohibited List, under S4 Hormone and Metabolic Modulators → S4.4 (Metabolic Modulators), specifically S4.4.1 (AMPK activators), where it’s listed by name. Another drug, the PPARδ agonist GW1516 (GW501516/Cardarine), sits in the same S4.4 section. This is true on the 2026 Prohibited List (which also names BAM15 and MOTS-c as AMPK-activator examples). AICAR is not a SARM — those are a separate category (S1.2). USADA’s page for athletes confirms the same framing: prohibited at all times, experimental, and not approved for human use.

Safety

• Most of what we know about its safety comes from short IV infusions given in monitored hospital settings, not from people dosing themselves long-term — a very different situation from how biohackers use it.
• At higher IV doses, the reported dose-related side effects include high uric acid levels (hyperuricemia), temporary drops in red blood cells (anemia) and/or platelets (thrombocytopenia), reduced kidney function, and a drop in blood pressure during infusion (hypotension). Lower doses were generally tolerated well in the trials.
• Real unknowns for biohacking use: there are no long-term human safety data; the body absorbs it poorly when taken by mouth (medical use was always IV, so oral products are a poor fit for what the evidence actually tested); research-chemical products aren’t checked for purity or identity; and constantly switching on AMPK — or hitting unintended targets — raises theoretical worries. USADA specifically warns about possible health risks. This is not a harmless compound.
• In short: an experimental compound with no approved human use, banned in sport, unproven for any biohacking goal, and with real (if dose-dependent) toxicities already documented in trials.

Bottom line

AICAR (acadesine) is a small-molecule AMPK activator — not a peptide — and its “exercise in a pill” fame rests almost entirely on a single 2008 mouse study. The only human track record is in two failed or stalled medical programs (protecting the heart during surgery, which came back negative in a large trial, and a blood cancer, which never advanced) plus one short glucose-uptake study that, tellingly, showed no muscle AMPK activation. There is no credible human evidence for endurance, fat loss, recovery, longevity, or appearance. It is an unapproved experimental drug sold only as a research chemical, banned in sport at all times, with documented dose-dependent toxicities and no long-term human safety data.

Evidence grade: 1/10 · Unsupported.

Sources

• Narkar VA, Evans RM, et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008;134(3):405–415. PMID 18674809.
• Cuthbertson DJ, et al. 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007;56(8):2078–2084. PMID 17513706.
• Newman MF, et al. (RED-CABG). Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with CABG: the RED-CABG randomized controlled trial. JAMA 2012;308(2):157–164. PMID 22782417.
• Campàs C, et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003;101(9):3674–3680. PMID 12522004.
• Van Den Neste E, et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia: a multicenter phase I/II study. Cancer Chemother Pharmacol 2013;71(3):581–591. PMID 23228986; PMC3579463.
• Višnjić D, et al. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells 2021;10(5):1095. PMC8147799.
• WADA. The Prohibited List (2026; S4.4 Metabolic Modulators — S4.4.1 AMPK activators).
• USADA. What Athletes Should Know About AICAR and Other Prohibited AMP-Activated Protein Kinase Activators.
• Mangano DT (McSPI). Effects of acadesine on myocardial infarction, stroke, and death following surgery: a meta-analysis of the 5 international randomized trials. JAMA 1997;277(4):325–332. PMID 9002496.